Liquidia to Participate in the Jefferies London Healthcare Conference
November 11, 2021 16:30 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer of Liquidia, will provide an update on the...
FDA Grants Tentative Approval for Liquidia’s YUTREPIA™ (Treprostinil) Inhalation Powder
November 08, 2021 05:45 ET
|
Liquidia Corporation
First dry-powder formulation of treprostinil to meet criteria required for FDA approvalFinal FDA approval may occur in October 2022 or earlier upon resolution of on-going litigationConference call and...
Liquidia Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 03, 2021 16:55 ET
|
Liquidia Corporation
- Increased adoption of generic Treprostinil Injection by patients, physicians and payers- Completed on-site pre-approval inspections by FDA of two U.S. manufacturing facilities- Anticipate FDA...
Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent
October 08, 2021 17:23 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes...
Liquidia to Participate at H.C. Wainwright 23rd Annual Global Investment Conference
September 10, 2021 08:29 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Damian deGoa, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual...
FDA Completes On-site Pre-Approval Inspection of Liquidia’s Morrisville, North Carolina Facility
August 18, 2021 16:15 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has completed an on-site Pre-Approval...
U.S. Patent Trial and Trademark Appeal Board Decides to Institute Inter Partes Review of United Therapeutics’ Tyvaso® Patent
August 12, 2021 08:00 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR)...
Liquidia Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 10, 2021 07:00 ET
|
Liquidia Corporation
Launched subcutaneous delivery of Treprostinil Injection, doubling market opportunityResubmitted New Drug Application (NDA) for LIQ861 (treprostinil) inhalation powderImproved balance sheet with...
Liquidia to Report Second Quarter 2021 Financial Results on August 10, 2021
August 03, 2021 07:00 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2021 financial results on Tuesday, August 10, 2021....
Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder
June 02, 2021 07:00 ET
|
Liquidia Corporation
MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA)...